Biofrontera Stock Earnings Reports

Biofrontera reported a strong Q1 2026 driven by its October 2025 strategic transaction which transferred full U.S. ownership of Ameluz and RhodoLED to Biofrontera Inc. Product revenue rose 17% year-over-year to $10.1M (Ameluz unit volume +16%), gross margin expanded to ~80% (vs ~62% prior year) due to a new earnout structure replacing prior transfer pricing, and cash used in operations was nearly zero ($70k), signaling material progress toward cash-flow breakeven. Key commercial metrics: ~29,000 Ameluz tubes sold in Q1, ~773 installed RhodoLED lamps across 709 offices (32 lamp placements in Q1). Clinical/regulatory progress: FDA accepted an sNDA for Ameluz PDT for superficial basal cell carcinoma with a PDUFA date of Sept 28, 2026; positive Phase III results for actinic keratosis (extremities, neck, trunk) supporting an sNDA planned for Q3 2026; encouraging Phase II acne data with plans to discuss Phase III design with FDA in H2 2026. SG&A rose (driven by a fully deployed salesforce, legal/patent costs and manufacturing transition costs), resulting in operating loss of $4.3M, but adjusted EBITDA improved to negative $3.6M (vs -$4.4M prior year). Balance sheet: $6.3M cash on March 31, 2026; going concern remains disclosed and management expects to pursue revenue growth, a $1M milestone from a prior divestiture and, if needed, a working capital facility to bridge. The company regained Nasdaq minimum bid price compliance in May 2026. Overall, investors should focus on margin leverage from the new cost structure, upcoming regulatory catalysts (sBCC PDUFA and AK sNDA), progress toward cash-flow breakeven, and potential future label expansions (acne and SCC in situ).